Search research articles
Contact Us
Filters
Showing results (491-500 of 499) with videos related to
Page
of 50
Sort By:
You have reached the last page of results.
This site can display upto 499 results.
JAMA Oncology
|
September 10, 2020
Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment
Stijn van Roessel, Eran van Veldhuisen, Sjors Klompmaker, et al.
Annals of Surgery
|
August 12, 2025
Surgical Complications in Patients with (borderline) Resectable Pancreatic Cancer after Neoadjuvant Therapy in the PREOPANC-2 Randomized Controlled Trial
Esther N Dekker, Rutger T Theijse, Jacob L van Dam, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 27, 2022
Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial
Eva Versteijne, Jacob L van Dam, Mustafa Suker, et al.
Annals of Surgery
|
January 31, 2025
Validation of the PANAMA Score for Survival and Benefit of Adjuvant Therapy in Patients With Resected Pancreatic Cancer after Neoadjuvant FOLFIRINOX
Ingmar F Rompen, Thomas F Stoop, Stijn van Roessel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 29, 2026
Thromboembolic Events During Perioperative Therapy for Resectable and Borderline Resectable Pancreatic Cancer in the PREOPANC-2 Trial
Ruth A L Willems, Aniek E van Diepen, Esther N Dekker, et al.
Journal of the National Cancer Institute
|
May 16, 2019
Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis
Quisette P Janssen, Stefan Buettner, Mustafa Suker, et al.
The Lancet. Oncology
|
September 13, 2025
Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial
Quisette P Janssen, Jacob L van Dam, Marlies L van Bekkum, et al.
The British Journal of Surgery
|
December 1, 2025
Delayed gastric emptying after pancreatic cancer surgery impacts time to start of adjuvant treatment but not overall survival: a post-hoc analysis of the PREOPANC-1 and -2 trials
Bo T M Strijbos, Imme Kraakman, Jana S Hopstaken, et al.
Brain : a Journal of Neurology
|
March 17, 2020
Consensus on the reporting and experimental design of clinical and cognitive-behavioural neurofeedback studies (CRED-nf checklist)
Tomas Ros, Stefanie Enriquez-Geppert, Vadim Zotev, et al.
Page
of 50
Search research articles
Search
Showing results (491-500 of 499) with videos related to
Sort By:
Page
of 50
You have reached the last page of results.
This site can display upto 499 results.
JAMA Oncology
|
September 10, 2020
Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment
Stijn van Roessel, Eran van Veldhuisen, Sjors Klompmaker, et al.
Annals of Surgery
|
August 12, 2025
Surgical Complications in Patients with (borderline) Resectable Pancreatic Cancer after Neoadjuvant Therapy in the PREOPANC-2 Randomized Controlled Trial
Esther N Dekker, Rutger T Theijse, Jacob L van Dam, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 27, 2022
Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial
Eva Versteijne, Jacob L van Dam, Mustafa Suker, et al.
Annals of Surgery
|
January 31, 2025
Validation of the PANAMA Score for Survival and Benefit of Adjuvant Therapy in Patients With Resected Pancreatic Cancer after Neoadjuvant FOLFIRINOX
Ingmar F Rompen, Thomas F Stoop, Stijn van Roessel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 29, 2026
Thromboembolic Events During Perioperative Therapy for Resectable and Borderline Resectable Pancreatic Cancer in the PREOPANC-2 Trial
Ruth A L Willems, Aniek E van Diepen, Esther N Dekker, et al.
Journal of the National Cancer Institute
|
May 16, 2019
Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis
Quisette P Janssen, Stefan Buettner, Mustafa Suker, et al.
The Lancet. Oncology
|
September 13, 2025
Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial
Quisette P Janssen, Jacob L van Dam, Marlies L van Bekkum, et al.
The British Journal of Surgery
|
December 1, 2025
Delayed gastric emptying after pancreatic cancer surgery impacts time to start of adjuvant treatment but not overall survival: a post-hoc analysis of the PREOPANC-1 and -2 trials
Bo T M Strijbos, Imme Kraakman, Jana S Hopstaken, et al.
Brain : a Journal of Neurology
|
March 17, 2020
Consensus on the reporting and experimental design of clinical and cognitive-behavioural neurofeedback studies (CRED-nf checklist)
Tomas Ros, Stefanie Enriquez-Geppert, Vadim Zotev, et al.
Page
of 50